The collaboration enables NextCell to further leverage its existing infrastructure and expertise in advanced cell handling, also beyond its own clinical projects, it states.

“The collaboration with OptiCell fits perfectly into our daily operations. We utilise existing staff and equipment within NextCell and will also purchase services from our subsidiaries QVance and Cellaviva,” says Mathias Svahn, CEO of NextCell Pharma AB.

A welcome contribution to the ongoing development of ProTrans

Under the agreement, OptiCell is responsible for donor and customer relations, including planning and managing the apheresis operations at its clinic in Huddinge (Novum Labs). NextCell is responsible for cell handling, freezing, storage, and logistics.

The revenue generated from these services also provides a welcome contribution to the ongoing development of ProTrans, the company’s lead drug candidate for the treatment of type 1 diabetes, it states.

“The collaboration with NextCell Pharma allows us to achieve more advanced cell management and increase flexibility in delivering high-quality cell products for cell and gene therapies,” says Jarmo Henriksson, CEO of OptiCell Solutions AB.